Takeda sees ixazomib combo results posted; zasocitinib Phase 2 vitiligo trial active

Two Takeda-linked studies had registry updates this period, one reporting results and one confirming ongoing status without new enrollment.

• A Phase I/II trial combining ixazomib citrate with pomalidomide, clarithromycin, and dexamethasone in double refractory multiple myeloma, sponsored by Joseph Tuscano with Takeda and Celgene as collaborators, is listed as completed with 32 participants enrolled¹. The study sought to establish a maximum tolerated dose and recommended Phase 2 dose, and to determine complete response and stringent complete response rates in patients with multiple myeloma refractory to bortezomib and lenalidomide¹, with results first posted 2026-11-02.
• Takeda's Phase 2 trial of zasocitinib (TAK-279) in nonsegmental vitiligo is listed as active, not recruiting, with an estimated enrollment of 200 participants². The primary endpoint is the percentage of participants achieving at least 75% improvement from baseline in Facial Vitiligo Area Scoring Index (F-VASI) at Week 24², with primary completion estimated for 2027-10-12.